Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates

Dow Jones

2024-11-02

By Jasmine Li

Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer.

The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year.

After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with Sanofi.

The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease.

Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter.

The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in the first quarter.

Write to Jasmine Li at jasmine.li@wsj.com

(END) Dow Jones Newswires

November 01, 2024 15:05 ET (19:05 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2480567778"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480567778\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2480567778?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-02 03:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480567778","market":"us","top_or_hot":-1,"title":"Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Jasmine Li \n</p>\n<p>\n  Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer. \n</p>\n<p>\n  The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year. \n</p>\n<p>\n  After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>. \n</p>\n<p>\n  The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease. \n</p>\n<p>\n  Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter. \n</p>\n<p>\n  The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in the first quarter. \n</p>\n<p>\n  Write to Jasmine Li at jasmine.li@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 15:05 ET (19:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-02 03:05</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Jasmine Li \n</p>\n<p>\n  Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer. \n</p>\n<p>\n  The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year. \n</p>\n<p>\n  After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>. \n</p>\n<p>\n  The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease. \n</p>\n<p>\n  Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter. \n</p>\n<p>\n  The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in the first quarter. \n</p>\n<p>\n  Write to Jasmine Li at jasmine.li@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 01, 2024 15:05 ET (19:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2480567778","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480567778","pubTimestamp":1730487900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer.The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year.After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with Sanofi.The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease.Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter.The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","VIR":"Vir Biotechnology, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4568":"美国抗疫概念","SNYNF":"Sanofi","BK4007":"制药"},"translate_title":"Vir股价因与赛诺菲达成癌症许可协议和试验更新而上涨25%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"VIR":0.9},"content_text":"By Jasmine Li \n\n\n  Shares of Vir Biotechnology surged after the company provided updates on its pipeline of potential treatments for hepatitis and cancer. \n\n\n  The stock rose 25% to $9.34 in midday trading on Friday. Shares are down 8.5% this year. \n\n\n  After the market closed on Thursday Vir reported lower revenue and a wider loss in the third quarter, citing higher research and development expenses from the closing its licensing deal with Sanofi. \n\n\n  The deal gives Vir the exclusive worldwide license to three T-cell engager programs with potential applications in a range of cancers, the company said. Vir also gained exclusive use of a proprietary masking platform for oncology and infectious disease. \n\n\n  Vir said it will present additional data from its chronic hepatitis trials in November, and plans to share further data assessing a potential functional cure in the second quarter. \n\n\n  The San Francisco company also said it plans to release initial clinical data for VIR-5500, a treatment designed to minimize off-tumor toxicity in the first quarter. \n\n\n  Write to Jasmine Li at jasmine.li@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 01, 2024 15:05 ET (19:05 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}